OMEROS CORP (OMER) Stock Price, Quote, News and Overview
NASDAQ:OMER - Nasdaq - US6821431029 - Common Stock - Currency: USD
OMER Quote, Performance and Key Statistics
3.48
-0.03 (-0.85%)
The current stock price of OMER is 3.48 USD. In the past month the price increased by 8.41%. In the past year, price decreased by -28.69%.
OMER Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 55.34 | 721.70B | ||
| JNJ | JOHNSON & JOHNSON | 16.3 | 392.14B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 17.89 | 290.11B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.07 | 226.19B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 15.92 | 214.74B | ||
| MRK | MERCK & CO. INC. | 10.46 | 204.70B | ||
| PFE | PFIZER INC | 7.66 | 139.75B | ||
| SNY | SANOFI-ADR | 10.79 | 118.47B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.55 | 97.81B | ||
| GSK | GSK PLC-SPON ADR | 8.25 | 73.78B | ||
| ZTS | ZOETIS INC | 24.92 | 66.79B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 64.09 | 46.04B |
Related stock screener links
About OMER
Company Profile
Omeros Corp. operates as a biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 202 full-time employees. The company went IPO on 2009-10-08. The firm is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Company Info
OMEROS CORP
201 Elliott Avenue West
Seattle WASHINGTON 98119 US
CEO: Gregory A. Demopulos
Employees: 202
Phone: 12066765000
OMEROS CORP / OMER FAQ
What is the stock price of OMEROS CORP today?
The current stock price of OMER is 3.48 USD. The price decreased by -0.85% in the last trading session.
What is the ticker symbol for OMEROS CORP stock?
The exchange symbol of OMEROS CORP is OMER and it is listed on the Nasdaq exchange.
On which exchange is OMER stock listed?
OMER stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for OMEROS CORP stock?
11 analysts have analysed OMER and the average price target is 30.6 USD. This implies a price increase of 779.31% is expected in the next year compared to the current price of 3.48. Check the OMEROS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is OMEROS CORP worth?
OMEROS CORP (OMER) has a market capitalization of 203.89M USD. This makes OMER a Micro Cap stock.
How many employees does OMEROS CORP have?
OMEROS CORP (OMER) currently has 202 employees.
What are the support and resistance levels for OMEROS CORP (OMER) stock?
OMEROS CORP (OMER) has a support level at 3.26 and a resistance level at 3.63. Check the full technical report for a detailed analysis of OMER support and resistance levels.
Should I buy OMEROS CORP (OMER) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of OMER, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of OMER, evaluating the profitability, health, valuation and growth aspects
- OMEROS CORP (OMER) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- OMEROS CORP (OMER) Sales and EPS estimates to see what analysts future expectations are.
- OMEROS CORP (OMER) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- OMEROS CORP (OMER) Insider and Institutional Ownership to learn about the owners and their transactions.
- OMEROS CORP (OMER) Stock Chart to make your own analysis
- OMEROS CORP (OMER) Latest news and press-releases to stay up to date.
Does OMEROS CORP (OMER) stock pay dividends?
OMER does not pay a dividend.
When does OMEROS CORP (OMER) report earnings?
OMEROS CORP (OMER) will report earnings on 2025-08-06.
What is the Price/Earnings (PE) ratio of OMEROS CORP (OMER)?
OMEROS CORP (OMER) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.65).
What is the Short Interest ratio of OMEROS CORP (OMER) stock?
The outstanding short interest for OMEROS CORP (OMER) is 24.14% of its float. Check the ownership tab for more information on the OMER short interest.
OMER Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to OMER. When comparing the yearly performance of all stocks, OMER is a bad performer in the overall market: 95.88% of all stocks are doing better.
OMER Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to OMER. OMER may be in some trouble as it scores bad on both profitability and health.
OMER Financial Highlights
Over the last trailing twelve months OMER reported a non-GAAP Earnings per Share(EPS) of -2.65. The EPS decreased by -34.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -65.08% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
OMER Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to OMER. The Buy consensus is the average rating of analysts ratings from 11 analysts.